{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:15:16Z","timestamp":1778832916893,"version":"3.51.4"},"reference-count":116,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["158989968 - SFB 900"],"award-info":[{"award-number":["158989968 - SFB 900"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.coviro.2023.101362","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T01:44:52Z","timestamp":1693964692000},"page":"101362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Genetic and pharmacological perturbation of hepatitis-C virus entry"],"prefix":"10.1016","volume":"62","author":[{"given":"Bel\u00e9n","family":"Carriqu\u00ed-Madro\u00f1al","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Lasswitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"von Hahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1326-5038","authenticated-orcid":false,"given":"Gisa","family":"Gerold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2023.101362_bib1","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/381667a0","article-title":"HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5","volume":"381","author":"Dragic","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2023.101362_bib2","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/381661a0","article-title":"Identification of a major co-receptor for primary isolates of HIV-1","volume":"381","author":"Deng","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2023.101362_bib3","doi-asserted-by":"crossref","first-page":"30603","DOI":"10.1074\/jbc.272.49.30603","article-title":"Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32","volume":"272","author":"Benkirane","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2023.101362_bib4","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus","volume":"461","author":"Thomas","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2023.101362_bib5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/ng.2521","article-title":"A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus","volume":"45","author":"Prokunina-Olsson","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.coviro.2023.101362_bib6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2023.101362_bib7","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S1471-4914(02)02395-X","article-title":"Hepatitis C: molecular virology and antiviral targets","volume":"8","author":"Moradpour","year":"2002","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.coviro.2023.101362_sbref8","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1093\/emboj\/cdf529","article-title":"The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus","volume":"21","author":"Scarselli","year":"2002","journal-title":"EMBO J"},{"key":"10.1016\/j.coviro.2023.101362_sbref9","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1126\/science.282.5390.938","article-title":"Binding of hepatitis C virus to CD81","volume":"282","author":"Pileri","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.coviro.2023.101362_sbref10","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nature05654","article-title":"Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry","volume":"446","author":"Evans","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2023.101362_sbref11","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/nature07684","article-title":"Human occludin is a hepatitis C virus entry factor required for infection of mouse cells","volume":"457","author":"Ploss","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2023.101362_bib12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jhep.2006.09.024","article-title":"The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus","volume":"46","author":"Molina","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2023.101362_bib13","doi-asserted-by":"crossref","first-page":"12766","DOI":"10.1073\/pnas.96.22.12766","article-title":"Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor","volume":"96","author":"Agnello","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2023.101362_bib14","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/jmv.10196","article-title":"Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption","volume":"68","author":"Germi","year":"2002","journal-title":"J Med Virol"},{"key":"10.1016\/j.coviro.2023.101362_bib15","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1086\/507647","article-title":"In vitro interaction between hepatitis C virus (HCV) envelope glycoprotein E2 and serum lipoproteins (LPs) results in enhanced cellular binding of both HCV E2 and LPs","volume":"194","author":"Wunschmann","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2023.101362_bib16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.virol.2009.08.037","article-title":"Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor","volume":"394","author":"Owen","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2023.101362_bib17","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/hep.25501","article-title":"Role of low-density lipoprotein receptor in the hepatitis C virus life cycle","volume":"55","author":"Albecka","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2023.101362_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005610","article-title":"Lipoprotein receptors redundantly participate in entry of hepatitis C virus","volume":"12","author":"Yamamoto","year":"2016","journal-title":"PLoS Pathog"},{"issue":"7","key":"10.1016\/j.coviro.2023.101362_bib19","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.3390\/cells10071626","article-title":"Interdependent impact of lipoprotein receptors and lipid-lowering drugs on HCV infectivity","volume":"10","author":"Zapatero-Belinch\u00f3n","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.coviro.2023.101362_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004233","article-title":"Secretion of hepatitis C virus envelope glycoproteins depends on assembly of apolipoprotein B positive lipoproteins","volume":"4","author":"Icard","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2023.101362_bib21","doi-asserted-by":"crossref","first-page":"6919","DOI":"10.1128\/JVI.76.14.6919-6928.2002","article-title":"Characterization of low- and very-low-density hepatitis C virus RNA-containing particles","volume":"76","author":"Andr\u00e9","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2023.101362_bib22","doi-asserted-by":"crossref","first-page":"31242","DOI":"10.1074\/jbc.M112.365924","article-title":"Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps","volume":"287","author":"Dao Thi","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2023.101362_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007111","article-title":"Hepatitis C virus enters liver cells using the CD81 receptor complex proteins calpain-5 and CBLB","volume":"14","author":"Bruening","year":"2018","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2023.101362_bib24","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm.2341","article-title":"EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy","volume":"17","author":"Lupberger","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2023.101362_bib25","doi-asserted-by":"crossref","first-page":"C611","DOI":"10.1152\/ajpcell.00622.2008","article-title":"Control of tight junctional sealing: roles of epidermal growth factor and prostaglandin E2","volume":"297","author":"Flores-Benitez","year":"2009","journal-title":"Am J Physiol, Cell Physiol"},{"key":"10.1016\/j.coviro.2023.101362_bib26","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.chom.2018.02.005","article-title":"Single particle imaging of polarized hepatoma organoids upon hepatitis C virus infection reveals an ordered and sequential entry process","volume":"23","author":"Baktash","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coviro.2023.101362_bib27","doi-asserted-by":"crossref","first-page":"8316","DOI":"10.1128\/JVI.00665-08","article-title":"CD81 is a central regulator of cellular events required for hepatitis C virus infection of human hepatocytes","volume":"82","author":"Brazzoli","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2023.101362_bib28","first-page":"401","article-title":"Hepatitis C virus internalization","volume":"17","author":"Zona","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2023.101362_bib29","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1128\/JVI.02286-07","article-title":"CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry","volume":"82","author":"Harris","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2023.101362_bib30","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.chom.2013.02.006","article-title":"HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex","volume":"13","author":"Zona","year":"2013","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coviro.2023.101362_bib31","doi-asserted-by":"crossref","first-page":"10777","DOI":"10.1073\/pnas.1301764110","article-title":"Identification of transferrin receptor 1 as a hepatitis C virus entry factor","volume":"110","author":"Martin","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2023.101362_bib32","doi-asserted-by":"crossref","first-page":"8012","DOI":"10.1128\/JVI.00038-09","article-title":"The tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection","volume":"83","author":"Benedicto","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2023.101362_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003244","article-title":"Temporal analysis of hepatitis C virus cell entry with occludin directed blocking antibodies","volume":"9","author":"Sourisseau","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2023.101362_bib34","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/hep.26733","article-title":"Critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry","volume":"59","author":"Douam","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2023.101362_bib35","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1128\/JVI.06996-11","article-title":"Hepatitis C virus induces CD81 and claudin-1 endocytosis","volume":"86","author":"Farquhar","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2023.101362_bib36","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1128\/JVI.00024-06","article-title":"Hepatitis C virus entry depends on clathrin-mediated endocytosis","volume":"80","author":"Blanchard","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2023.101362_bib37","doi-asserted-by":"crossref","first-page":"11571","DOI":"10.1128\/JVI.01717-06","article-title":"Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles","volume":"80","author":"Meertens","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2023.101362_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000702","article-title":"RNA interference and single particle tracking analysis of hepatitis C virus endocytosis","volume":"5","author":"Coller","year":"2009","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2023.101362_bib39","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1096\/fj.09-131920","article-title":"Kinases required in hepatitis C virus entry and replication highlighted by small interference RNA screening","volume":"23","author":"Trotard","year":"2009","journal-title":"FASEB J"},{"key":"10.1016\/j.coviro.2023.101362_bib40","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.celrep.2015.06.063","article-title":"Quantitative proteomics identifies serum response factor binding protein 1 as a host factor for hepatitis C virus entry","volume":"12","author":"Gerold","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.coviro.2023.101362_bib41","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nm.2581","article-title":"Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor","volume":"18","author":"Sainz","year":"2012","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.coviro.2023.101362_bib42","doi-asserted-by":"crossref","first-page":"a036830","DOI":"10.1101\/cshperspect.a036830","article-title":"Hepatitis C virus entry: protein interactions and fusion determinants governing productive hepatocyte invasion","volume":"10","author":"Gerold","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.coviro.2023.101362_bib43","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1128\/JVI.80.4.1734-1741.2006","article-title":"Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry","volume":"80","author":"Tscherne","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2023.101362_sbref44","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41586-021-03913-5","article-title":"Structural insights into hepatitis C virus receptor binding and entry","volume":"598","author":"Kumar","year":"2021","journal-title":"Nature"},{"issue":"7768","key":"10.1016\/j.coviro.2023.101362_bib45","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41586-019-1373-2","article-title":"A human liver cell atlas reveals heterogeneity and epithelial progenitors","volume":"572","author":"Aizarani","year":"2019","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.coviro.2023.101362_bib46","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jhep.2020.09.003","article-title":"Liver zonation","volume":"74","author":"Manco","year":"2021","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.coviro.2023.101362_bib47","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/hep.22028","article-title":"Hepatitis C virus receptor expression in normal and diseased liver tissue","volume":"47","author":"Reynolds","year":"2008","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.coviro.2023.101362_bib48","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jhep.2016.07.048","article-title":"High resolution sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end-stage liver disease","volume":"66","author":"Hedegaard","year":"2017","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.coviro.2023.101362_bib49","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0092-8674(00)80110-5","article-title":"Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection","volume":"86","author":"Liu","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2023.101362_sbref50","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.antiviral.2013.10.018","article-title":"Impact of single nucleotide polymorphisms in the essential HCV entry factor CD81 on HCV infectivity and neutralization","volume":"101","author":"Deest","year":"2014","journal-title":"Antivir Res"},{"key":"10.1016\/j.coviro.2023.101362_sbref51","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00430-020-00675-1","article-title":"Single-nucleotide variants in human CD81 influence hepatitis C virus infection of hepatoma cells","volume":"209","author":"Alberione","year":"2020","journal-title":"Med Microbiol Immunol"},{"issue":"28","key":"10.1016\/j.coviro.2023.101362_bib52","doi-asserted-by":"crossref","first-page":"5158","DOI":"10.3748\/wjg.v23.i28.5158","article-title":"Single amino acid mutation of SR-BI decreases infectivity of hepatitis C virus derived from cell culture in a cell culture model","volume":"23","author":"Gao","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.coviro.2023.101362_bib53","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2017.03.020","article-title":"Scavenger receptor class B member 1 (SCARB1) variants modulate hepatitis C virus replication cycle and viral load","volume":"67","author":"Westhaus","year":"2017","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.coviro.2023.101362_bib54","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jhep.2017.04.013","volume":"67","author":"Colpitts","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2023.101362_bib55","doi-asserted-by":"crossref","first-page":"7613","DOI":"10.1128\/JVI.00212-11","article-title":"Impact of intra- and interspecies variation of occludin on its function as coreceptor for authentic hepatitis C virus particles","volume":"85","author":"Ciesek","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2023.101362_bib56","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2893.2009.01166.x","article-title":"Genetic variation in CLDN1 and susceptibility to hepatitis C virus infection","volume":"17","author":"Bekker","year":"2010","journal-title":"J Viral Hepat"},{"issue":"8","key":"10.1016\/j.coviro.2023.101362_bib57","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/gene.2015.38","article-title":"Polymorphisms in EGFR and IL28B are associated with spontaneous clearance in an HCV-infected Iranian population","volume":"16","author":"Carapito","year":"2015","journal-title":"Genes Immun"},{"key":"10.1016\/j.coviro.2023.101362_bib58","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1399-0004.2011.01682.x","article-title":"Novel mutations in scavenger receptor BI associated with high HDL cholesterol in humans","volume":"79","author":"Brunham","year":"2011","journal-title":"Clin Genet"},{"key":"10.1016\/j.coviro.2023.101362_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0045660","article-title":"Functional characterization of newly-discovered mutations in human SR-BI","volume":"7","author":"Chadwick","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2023.101362_bib60","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.1128\/JVI.80.10.4940-4948.2006","article-title":"Different domains of CD81 mediate distinct stages of hepatitis C virus pseudoparticle entry","volume":"80","author":"Bertaux","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2023.101362_bib61","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1128\/JVI.74.8.3642-3649.2000","article-title":"Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2","volume":"74","author":"Higginbottom","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2023.101362_sbref62","doi-asserted-by":"crossref","first-page":"11331","DOI":"10.1128\/JVI.00104-06","article-title":"Diverse CD81 proteins support hepatitis C virus infection","volume":"80","author":"Flint","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2023.101362_bib63","doi-asserted-by":"crossref","first-page":"7844","DOI":"10.1128\/JVI.00029-06","article-title":"A conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and viral entry","volume":"80","author":"Drummer","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2023.101362_bib64","doi-asserted-by":"crossref","first-page":"8695","DOI":"10.1128\/JVI.00271-06","article-title":"Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding","volume":"80","author":"Owsianka","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2023.101362_bib65","article-title":"A neutralization epitope in the hepatitis C virus E2 glycoprotein interacts with host entry factor CD81","volume":"9","author":"Zhao","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.coviro.2023.101362_sbref66","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3390\/v10040207","article-title":"CD81 receptor regions outside the large extracellular loop determine hepatitis C virus entry into hepatoma cells","volume":"10","author":"Banse","year":"2018","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.coviro.2023.101362_bib67","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1128\/JVI.01134-06","article-title":"Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I","volume":"81","author":"Kapadia","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2023.101362_bib68","doi-asserted-by":"crossref","first-page":"16931","DOI":"10.1074\/jbc.RA120.014761","article-title":"Cholesterol sensing by CD81 is important for hepatitis C virus entry","volume":"295","author":"Palor","year":"2020","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.coviro.2023.101362_bib69","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01799-16","article-title":"Mice expressing minimally humanized CD81 and occludin genes support hepatitis C virus uptake in vivo","volume":"91","author":"Ding","year":"2017","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.coviro.2023.101362_bib70","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01915-16","article-title":"Expanding the host range of hepatitis C virus through viral adaptation","volume":"7","author":"von Schaewen","year":"2016","journal-title":"MBio"},{"key":"10.1016\/j.coviro.2023.101362_bib71","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/hep.27773","article-title":"Hepatitis C virus infects rhesus macaque hepatocytes and simianized mice","volume":"62","author":"Scull","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2023.101362_bib72","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature12427","article-title":"Completion of the entire hepatitis C virus life cycle in genetically humanized mice","volume":"501","author":"Dorner","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2023.101362_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2013.05.036","article-title":"Recapitulation of the hepatitis C virus life-cycle in engineered murine cell lines","volume":"444","author":"Vogt","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2023.101362_bib74","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.virusres.2018.02.016","article-title":"Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: considerations for scientists and funding agencies","volume":"248","author":"Bartenschlager","year":"2018","journal-title":"Virus Res"},{"key":"10.1016\/j.coviro.2023.101362_bib75","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1053\/j.gastro.2018.10.024","article-title":"Status of direct-acting antiviral therapy for hepatitis C virus infection and remaining challenges","volume":"156","author":"Baumert","year":"2019","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.coviro.2023.101362_bib76","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1093\/cid\/ciac272","article-title":"High rate of hcv reinfection among recently injecting drug users: results from the trap hep c program \u2014 a prospective nationwide, population-based study","volume":"75","author":"Johannesson","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2023.101362_bib77","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s11901-013-0187-1","article-title":"Opportunities and risks of host-targeting antiviral strategies for hepatitis C","volume":"12","author":"Gerold","year":"2013","journal-title":"Curr Hepatol Rep"},{"key":"10.1016\/j.coviro.2023.101362_bib78","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nm0511-542","article-title":"Locking out hepatitis C","volume":"17","author":"Gerold","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2023.101362_bib79","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1161\/ATVBAHA.109.191320","article-title":"Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor","volume":"29","author":"Masson","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.coviro.2023.101362_bib80","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jhep.2010.06.024","article-title":"Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors","volume":"54","author":"Syder","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2023.101362_bib81","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/infdis\/jir802","article-title":"Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals","volume":"205","author":"Zhu","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2023.101362_bib82","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/infdis\/jit503","article-title":"Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study","volume":"209","author":"Sulkowski","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2023.101362_bib83","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1021\/ml500154q","article-title":"Indolinyl-Thiazole based inhibitors of Scavenger Receptor-BI (SR-BI)-mediated lipid transport","volume":"6","author":"Dockendorff","year":"2015","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.coviro.2023.101362_bib84","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1002\/hep.27196","article-title":"Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents","volume":"60","author":"Vercauteren","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2023.101362_bib85","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/hep.22547","article-title":"Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo","volume":"48","author":"Meuleman","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2023.101362_bib86","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064221","article-title":"A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission","volume":"8","author":"Fofana","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2023.101362_bib87","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000492","article-title":"Safety and antiviral activity of EGFR inhibition by erlotinib in chronic hepatitis C patients: a phase ib randomized controlled trial","volume":"13","author":"Saviano","year":"2022","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.coviro.2023.101362_bib88","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.26898","article-title":"Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma","volume":"59","author":"Fuchs","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2023.101362_bib89","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2017.01129","article-title":"Abl tyrosine kinase regulates hepatitis C virus entry","volume":"8","author":"Min","year":"2017","journal-title":"Front Microbiol"},{"key":"10.1016\/j.coviro.2023.101362_bib90","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1053\/j.gastro.2010.05.073","article-title":"Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes","volume":"139","author":"Fofana","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2023.101362_sbref91","doi-asserted-by":"crossref","first-page":"8282","DOI":"10.1128\/JVI.01102-13","article-title":"Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission","volume":"87","author":"Catanese","year":"2013","journal-title":"J Virol"},{"issue":"8","key":"10.1016\/j.coviro.2023.101362_bib92","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02258-17","article-title":"Monoclonal antibodies against occludin completely prevented hepatitis C virus infection in a mouse model","volume":"92","author":"Shimizu","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2023.101362_bib93","doi-asserted-by":"crossref","first-page":"8132","DOI":"10.1073\/pnas.0500269102","article-title":"The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)","volume":"102","author":"Garcia-Calvo","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2023.101362_bib94","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096533","article-title":"Matrix conditions and KLF2-dependent induction of heme oxygenase-1 modulate inhibition of HCV replication by fluvastatin","volume":"9","author":"Wuestenberg","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2023.101362_bib95","doi-asserted-by":"crossref","first-page":"15865","DOI":"10.1073\/pnas.2237238100","article-title":"Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation","volume":"100","author":"Ye","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2023.101362_bib96","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.antiviral.2016.02.006","article-title":"Statins can exert dual, concentration dependent effects on HCV entry in vitro","volume":"128","author":"Blanchet","year":"2016","journal-title":"Antivir Res"},{"key":"10.1016\/j.coviro.2023.101362_bib97","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1002\/hep.26190","article-title":"Characterization of the inhibition of hepatitis C virus entry by in vitro-generated and patient-derived oxidized low-density lipoprotein","volume":"57","author":"Westhaus","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2023.101362_bib98","doi-asserted-by":"crossref","first-page":"9505","DOI":"10.1073\/pnas.1307527110","article-title":"Ultrastructural analysis of hepatitis C virus particles","volume":"110","author":"Catanese","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2023.101362_bib99","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1074\/jbc.M110.175018","article-title":"Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome","volume":"286","author":"Merz","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2023.101362_bib100","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.1128\/JVI.76.12.5974-5984.2002","article-title":"Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex","volume":"76","author":"Egger","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2023.101362_bib101","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1073\/pnas.0700760104","article-title":"Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins","volume":"104","author":"Huang","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2023.101362_bib102","series-title":"StatPearls","article-title":"Lipid lowering drug therapy","author":"Chhetry","year":"2022"},{"key":"10.1016\/j.coviro.2023.101362_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103469","article-title":"Fluvastatin mitigates SARS-CoV-2 infection in human lung cells","volume":"24","author":"Zapatero-Belinch\u00f3n","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.coviro.2023.101362_bib104","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.3748\/wjg.15.5020","article-title":"Do statins reduce hepatitis C RNA titers during routine clinical use?","volume":"15","author":"Forde","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.coviro.2023.101362_bib105","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1440-1746.2012.07267.x","article-title":"Combination of fluvastatin with pegylated interferon\/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b","volume":"28","author":"Atsukawa","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.coviro.2023.101362_bib106","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/hep.22916","article-title":"Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development","volume":"50","author":"Delang","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2023.101362_bib107","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/hep.21232","article-title":"Different anti-HCV profiles of statins and their potential for combination therapy with interferon","volume":"44","author":"Ikeda","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2023.101362_bib108","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.21139","article-title":"Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells","volume":"43","author":"von Hahn","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2023.101362_bib109","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.clinre.2010.11.001","article-title":"Oxidized low-density lipoprotein is associated with viral load and disease activity in patients with chronic hepatitis C","volume":"35","author":"Nakhjavani","year":"2011","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.coviro.2023.101362_bib110","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/nyas.12832","article-title":"Development of sofosbuvir for the treatment of hepatitis C virus infection","volume":"1358","author":"Lawitz","year":"2015","journal-title":"Ann N Y Acad Sci"},{"issue":"11","key":"10.1016\/j.coviro.2023.101362_bib111","doi-asserted-by":"crossref","first-page":"a036855","DOI":"10.1101\/cshperspect.a036855","article-title":"Interferon-free hepatitis C virus therapy","volume":"10","author":"Pawlotsky","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"7203","key":"10.1016\/j.coviro.2023.101362_bib112","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature07106","article-title":"Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA","volume":"454","author":"Saito","year":"2008","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.coviro.2023.101362_bib113","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13287-023-03235-5","article-title":"Generation of multilineage liver organoids with luminal vasculature and bile ducts from human pluripotent stem cells via modulation of Notch signaling","volume":"14","author":"Kim","year":"2023","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"10.1016\/j.coviro.2023.101362_bib114","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26410-9","article-title":"A human multi-lineage hepatic organoid model for liver fibrosis","volume":"12","author":"Guan","year":"2021","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.coviro.2023.101362_bib115","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/hep.22673","article-title":"Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs","volume":"49","author":"Gottwein","year":"2009","journal-title":"Hepatology"},{"issue":"7566","key":"10.1016\/j.coviro.2023.101362_bib116","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature14899","article-title":"SEC14L2 enables pan-genotype HCV replication in cell culture","volume":"524","author":"Saeed","year":"2015","journal-title":"Nature"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625723000627?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625723000627?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:04:22Z","timestamp":1778832262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625723000627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":116,"alternative-id":["S1879625723000627"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2023.101362","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic and pharmacological perturbation of hepatitis-C virus entry","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2023.101362","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101362"}}